title: [A cost-benefit analysis of the influenza H1N1 vaccination in the primary and junior school in Shanghai].
abstract: OBJECTIVE
  To evaluate the cost-benefit for the Influenza Type A H1N1 Virus (Influenzae H1N1) vaccination in Shanghai primary and junior schools.
  
  
  METHODS
  A semi-experiment study was selected to evaluate the cost-benefit for Influenza H1N1 vaccination in primary and junior schools in 6 districts of Shanghai, including 414 636 students in total. According to the voluntary principle, the students were divided into the vaccinated group (233 445 students) and control group (181 191 students). The information of vaccine cost was collected from CDC in 19 districts in Shanghai by questionnaire; and the information of medical treatment cost was collected from questionnaire and abstracts of retrospective medical records, which included 31 mild cases and 15 severe cases. The cost-benefit analysis was conducted by health economic evaluation.
  
  
  RESULTS
  In total, there were 414 636 students enrolled in this study; while 233 445 (56.3%) students were in the vaccinated group and 181 191 in the control group. The attack rate in vaccinated group and control group was 0.61% (1433/233 445) and 1.76% (3166/181 191) respectively. The protection ratio was 65.34% ((1.76 - 0.61)/1.76) in the vaccinated group. The average cost of Influenza H1N1 was 36.81 yuan/person; and the average cost of medical treatment was (358.3 ± 243.6) yuan/mild case and (49 188.4 ± 99 917.3) yuan/severe case. The total benefit of vaccination in schools was 19 155 566.3 yuan, and the net benefit was 10 560 673.7 yuan. Therefore, the benefit-cost ratio was 2.24:1.
  
  
  CONCLUSIONS
  Influenza H1N1 vaccine could protect the students from Influenza H1N1 infection, and the cost-benefit analysis showed that the intervention strategy was worth trying.
authors.affiliation: Department of Epidemiology, School of Public Health, Fudan University; Key Laboratory of Public Health Safety, Ministry of Education, Shanghai 200032, China.
authors.forename: Gen-ming
authors.initials: GM
authors.lastname: Zhao
authors.forename: Jian
authors.initials: J
authors.lastname: Chen
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.forename: Hua
authors.initials: H
authors.lastname: Cai
authors.forename: Dan
authors.initials: D
authors.lastname: Wang
authors.forename: Bao-ke
authors.initials: BK
authors.lastname: Gu
authors.forename: Miao
authors.initials: M
authors.lastname: Yu
authors.forename: Xin
authors.initials: X
authors.lastname: Chen
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Zheng-an
authors.initials: ZA
authors.lastname: Yuan
mesh_terms: D000293:Adolescent; D002648:Child; D002681:China; D003362:Cost-Benefit Analysis; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000191:economics* / Q000276:immunology; D007251:Influenza, Human / Q000191:economics* / Q000517:prevention & control; D012574:Schools; D013334:Students
chemical_list: D007252:Influenza Vaccines